No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AMLX Amylyx Pharmaceuticals
- 1.980
- -0.020-1.00%
Close Apr 18 16:00 ET
- 1.990
- +0.010+0.51%
Post 18:09 ET
134.21MMarket Cap2.83P/E (TTM)
2.030High1.955Low1.03MVolume2.010Open2.000Pre Close2.06MTurnover2.03%Turnover Ratio2.83P/E (Static)67.78MShares31.21052wk High0.31P/B100.86MFloat Cap1.95552wk Low--Dividend TTM50.94MShs Float41.930Historical High--Div YieldTTM3.75%Amplitude1.955Historical Low1.991Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Amylyx Pharmaceuticals Inc (AMLX) and Rhythm Pharmaceuticals (RYTM)
Amylyx Pharmaceuticals: A Hold Rating Amidst Promising but Preliminary HELIOS Trial Results
Hold Rating on Amylyx Pharmaceuticals Amid Uncertainties in Drug Efficacy and Market Prospects
Amylyx Pharmaceuticals Is Maintained at Neutral by Baird
Amylyx Pharmaceuticals Is Maintained at Neutral by Baird
Express News | Baird Maintains Neutral on Amylyx Pharma, Lowers Price Target to $3
Express News | HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $8 Price Target
Comments
Update
$Amylyx Pharmaceuticals(AMLX.US$ Amylyx Pharmaceuticals Announces Interim Data From Phase 2 HELIOS Clinical Trial Of AMX0035 In Adults With Wolfram Syndrome
Benzinga· 4 mins ago
Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression
- All eight participants met prespecified r...
Benzinga· 4 mins ago
Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression
- All eight participants met prespecified r...
1
$Amylyx Pharmaceuticals(AMLX.US$
NEWS
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced positive interim data from the Phase 2 HELIOS clinical trial of AMX0035 in adults with Wolfram syndrome. The data showed improvements in pancreatic function, glycemic control, and vision, with all parti...
NEWS
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced positive interim data from the Phase 2 HELIOS clinical trial of AMX0035 in adults with Wolfram syndrome. The data showed improvements in pancreatic function, glycemic control, and vision, with all parti...
1
Analysts predict a revenue drop and higher losses per share for Amylyx Pharmaceuticals, indicating slower sales growth than the market, potentially causing market wariness.
1
But some good now! Hehehe
$Amylyx Pharmaceuticals(AMLX.US$ Amylyx Pharmaceuticals To Advance AMX0035 In Wolfram Syndrome And Progressive Supranuclear Palsy, And AMX0114 In Amyotrophic Lateral Sclerosis, Interim Data From Phase 2 Helios Trial Of AMX0035 For Wolfram Syndrome Are Expected In April 2024
1
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg